Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy

Breast Cancer

Volumn 10, Issue 1, 2003, Pages 33-37

  Kohno, Norio ^a   Kokufu, Ikuo ^b  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b Itami City Hospital   (Japan)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Prevention

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANIMAL; ANIMAL MODEL; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; METASTASIS; PATHOLOGY; REVIEW;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; MODELS, ANIMAL;

EID: 0041808973     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967623     Document Type: Review

References (25)

1. Arams HL Spiro R, Goldstein M: Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 3:74-76, 1950.
2. Coleman RE, Rubens RDI: The clinical course of bone metastases from breast cancer. BrJ Cancer 55:61-66, 1987. (Pubitemid 17234155)
3. Coleman RE: Skeletal complications of malignancy. Cancer 80 (suppl 8) :1588-1594, 1998. (Pubitemid 27444031)
4. Mundy GR and Yoneda T: Bisphosphonates as anticancer drugs. N Engl J Med 339:398-400, 1998. (Pubitemid 28363805)
5. Stewart AF, Margin M, Wu T, et al: Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Inves 81:932-938, 1988.
6. Powell GJ, Southby J, Danks JA, et al: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51:3059-3061, 1991.
7. Kohno N, Kitazawa S, Sakoda Y, et al: Parathyroid hormone-related protein in breast cancer tissues: relationship between primary and metastatic sites. Breast Cancer 1:43-49, 1994.
8. Roux S, Orcel P: Bone loss. Factors that regulate ostoclast differentiation: an up date. Arthritis Res 2:451-456, 2000. (Pubitemid 32223787)
9. Guise TA, Yin JJ, Taylor SD, et al: Evidence for causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549, 1996. (Pubitemid 26327863)
10. Krempien B, Manegold C: Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphopnate CL2MBP. Cancer 72:91-98, 1993. (Pubitemid 23182055)
11. Krempien B: Experimental findings on the osteoprotective potential of bisphosphonates against bone metastases and tumor-induced osteopathy: a pleading for an early and preventive administration, In: Orr FW and Singh G eds, Bone Metastases - Mechanisms and Pathophysiology, Landess, Gergetown, pp221-244.
12. Sasaki A, Boyce BF, Wright KR, et al: Bisphospho- hate residronate reduces metastatic human breast cancer burden in nude mice. Cancer Res 55:3551-3557, 1995.
13. Yoneda T, Sasaki A, Dunstan C, et al: Inhibition of osteolytic bone metastases of breast cancer by combined treatment with bisphosphonate and tissue inhibitor of matrix metalloproteinase-2. J Clin Invest 99:2509-2517, 1997. (Pubitemid 27227730)
14. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in woman with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999. (Pubitemid 29109314)
15. Hortobagyi GN, Theriault RL, Lipton A, et al: Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Media Breast Cancer Study Group.J Clin Oncol 16:2038-2044, 1998. (Pubitemid 28265038)
16. Coleman RE, Purohit OP, Black C, et al: Double-blind, randomized, placebo control, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncl 10:311-316, 1999. (Pubitemid 29217222)
17. Paterson AH, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral analysis of 1000 autopsied cases. Cancer 3:74-76, 1950.
18. Diel IJ, Solomayer EF, Bastert G, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. NEnglJMed 339:357-363, 1998. (Pubitemid 28363797)
19. Diel IJ: Bisphosphonates in prevention of bone metastases: current evidence. Semin Oncol 28(suppl 11):75-80, 2001. (Pubitemid 32844934)
20. Powel TJ, Paterson AHG, Nevantus A, et al: Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 17:468, 1998.
21. Saarto T, Blomqvist C, Virkkunen P, et al: Adjuvant clodronate treatment does not reduce the fl'equency of skeletal metastases in node-positive breast cancer patients: year results of a randomized control trial. J Clin Oneo119:10-17, 2001. (Pubitemid 32063474)
22. Kokufu I, Kohno N: Adjuvant pamidronate treatment reduces the incidence of bone metastases in patients with over 4 positive nodes. (submitted)
23. Paterson AHG: Adjuvant bisphosphonate therapy: the future. Sernin Onco128(suppl 11):81-85, 2001.
24. Hiller BE, Ingle JN, Berenson JR: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Onco118:1378-1391, 2000. (Pubitemid 30159858)
25. Smith R, Jipling W, Bryant J, et al: Primary breast cancer as risk factor for bone recurrence: NSABP Experience. Proc Am Soe Clin Oncol 18:1999.